NEW YORK, NY - A new study from researchers at Memorial Sloan-Kettering Cancer Center has found that the majority of surgeons treating prostate cancer in the United States have extremely low annual caseloads, potentially leading to increased rates of both surgical complications and cancer recurrence.
NEW YORK, NY - In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information. A new longitudinal study from researchers at Memorial Sloan-Kettering Cancer Center finds that while clinicians' and patients' reporting of treatment side effects are very different from each other, together they provide a more complete, clinically meaningful picture of the treatment experience.
NEW YORK, NY - There is concern that mastectomy is over-utilized in the United States, which raises questions about the role of surgeons and patient preference in treatment selection for breast cancer. New data from an observational study published in the October 14 issue of the Journal of the American Medical Association, a theme issue on surgical care, found that breast-conserving surgery was presented and provided in the majority of patients evaluated.
NEW YORK, NY - The new Evelyn H. Lauder Breast Center of Memorial Sloan-Kettering Cancer Center and the Memorial Sloan-Kettering Cancer Center Imaging Center have opened, offering patients the most advanced outpatient services for cancer diagnosis and breast cancer treatment and detection.
NEW YORK, NY - Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center.
NEW YORK, NY - Memorial Sloan-Kettering Cancer Center physician-scientist Charles L. Sawyers has been named a recipient of the 2009 Lasker~DeBakey Award for Clinical Medical Research.
NEW YORK, NY - Investigators at Memorial Sloan-Kettering Cancer Center, along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large-scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.
New research led by investigators at Memorial Sloan-Kettering Cancer Center sheds light on a genetic function that gives breast cancer cells the ability to survive and spread to the bone years after treatment has been administered.
NEW YORK, NY - A new study by researchers at Memorial Sloan-Kettering Cancer Center reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone - the two most prominent sites of lung cancer relapse.
NEW YORK, NY - A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don't require immediate surgery to remove the primary tumor in the colon.
NEW YORK, NY - A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC).
NEW YORK, NY - Charles Sawyers, MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center and a Howard Hughes Medical Institute investigator, has been named a "Dream Team" leader by Stand Up To Cancer and will co-lead a collaborative team that will receive $15 million to study targeted therapies to treat women's cancers.
NEW YORK, NY - New research led by investigators at Memorial Sloan-Kettering Cancer Center identifies three genes that specifically mediate the metastasis, or spread, of breast cancer to the brain and illuminates the mechanisms by which this spread occurs.
NEW YORK, NY - A novel, minimally invasive surgical approach to treat stomach cancer has been shown to have advantages that may make it a preferable treatment for some patients.
NEW YORK, NY - A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels - a marker for tumor growth - in men with advanced prostate cancer for whom traditional treatment options have failed.
NEW YORK, NY - Researchers at Memorial Sloan-Kettering Cancer Center have shown for the first time that a tendency to develop some blood disorders may be inherited.
New York, NY - The National Institutes of Health's National Cancer Institute has awarded The City College of New York and Memorial Sloan-Kettering Cancer Center a $15.9 million grant to implement a unique partnership in cancer research, education, and outreach.
NEW YORK, NY - The majority of young women at an increased risk of breast cancer due to chest radiation treatment for childhood cancer are not following breast cancer screening recommendations, according to a recently released, detailed assessment appearing in the January 28, 2009, issue of the Journal of the American Medical Association.
NEW YORK, NY - A new health policy report which will be published in the New England Journal of Medicine suggests that the swift and dramatic rise in cancer-drug spending is due to laws that keep Medicare from managing the use or price of cancer drugs. These laws limit Medicare's actions in cancer far more than they are limited in other areas of healthcare.
NEW YORK, NY - A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.
NEW YORK, NY - Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic.
NEW YORK, NY - Memorial Sloan-Kettering Cancer Center has announced the gift of a membership interest in Geoffrey Beene, LLC, the company that controls the business and fashion empire created by legendary designer Geoffrey Beene.
NEW YORK, NY - New findings from a Decision Analysis for the US Preventative Services Task Force (USPSTF) suggest that routine colorectal cancer screenings can be stopped in patients over the age of 75.
NEW YORK, NY - Memorial Sloan-Kettering Cancer Center and Summit Medical Group together announce a new collaborative relationship for the care of people with cancer.
NEW YORK, NY - American tennis player and World No. 8 ranked James Blake will formally announce today the launch of the Thomas Blake, Sr., Memorial Research Fund, which he established to support cancer research at Memorial Sloan-Kettering Cancer Center.
NEW YORK, NY - New data from a randomized, controlled trial found that acupuncture provided significant reductions in pain, dysfunction, and dry mouth in head and neck cancer patients after neck dissection.
NEW YORK, NY - New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.
NEW YORK, NY - A study led by researchers at Memorial Sloan-Kettering Cancer Center has uncovered how breast tumors use a particular type of molecule to promote metastasis - the spread of cancer cells.
NEW YORK, NY - Research led by investigators at Memorial Sloan-Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
NEW YORK, NY - The recent marketing of "at home" genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC).
NEW YORK - A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.
NEW YORK, NY - An international group of investigators led by scientists at Memorial Sloan-Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.
NEW YORK, NY - A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
NEW YORK, NY - A single prostate specific antigen (PSA) test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan-Kettering Cancer Center in New York and Lund University in Sweden.
NEW YORK, NY - The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan-Kettering Cancer Center is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers.
NEW YORK, NY - A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan-Kettering's new Brain Tumor Center (BTC).
NEW YORK, NY - Researchers have identified a specific group of microRNA molecules that are responsible for controlling genes that cause breast cancer metastasis.
NEW YORK, NY - Breast cancer risk varies widely among women who are carriers of the BRCA1 and BRCA2 mutations, according to a new study published in the January 9, 2008, issue of the Journal of the American Medical Association (JAMA).
New York, NY - A new study by researchers at Memorial Sloan-Kettering Cancer Center finds that even the sickest cancer patients are willing and able to "self-report" symptoms using the Internet, thus supplying key data in real time to their healthcare providers.
NEW YORK, NY - Three young investigators who have made major accomplishments in cancer research will be the recipients of the 2007 Paul Marks Prize for Cancer Research and will share a $150,000 award, announced Memorial Sloan-Kettering Cancer Center (MSKCC).
NEW YORK, NY - According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.
CHICAGO - A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.
CHICAGO - Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
NEW YORK - The Bright Horizons Foundation for Children, Memorial Sloan-Kettering Cancer Center (MSKCC), Abyssinian Development Corporation (ADC), and Community Playthings today cut ribbons to officially open Harlem's first Bright Space center for homeless children at Abyssinian House, a Tier II transitional residence serving the families of Harlem.
NEW YORK - philanthropist and art collector Iris Cantor has made a major commitment to Memorial Sloan-Kettering Cancer Center to create an endowed chair for a senior researcher in the field of digestive cancers.
NEW YORK - Patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.
NEW YORK - Biologists at Memorial Sloan-Kettering Cancer Center have identified a set of genes expressed in human breast cancer cells that work together to remodel the network of blood vessels at the site of the primary tumor.
NEW YORK - The first report of an international study looking at CT to screen current or former smokers for lung cancer found that screening did not reduce deaths from lung cancer.
NEW YORK - A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled antibody accurately identifies whether a patient has clear cell renal carcinoma - the most common and aggressive type of renal tumor - and arms the urologist with crucial information that will help determine whether surgery is needed.
NEW YORK - Nominations are currently being sought for the Paul Marks Prize for Cancer Research. This award, established by Memorial Sloan-Kettering Cancer Center (MSKCC) in 2001, is named for Paul A. Marks, MD, President Emeritus of the Center and a distinguished scientist.
QUEENS, NY - The Queens Library HealthLink initiative was developed to place libraries at the center of an innovative new effort designed to help medically underserved communities throughout Queens access free cancer information, early detection screenings, cancer treatment resources, and other life-saving services.
NEW YORK - Researchers led by scientists at Memorial Sloan-Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of PTEN function. The findings from two related studies are published in the January 12 issue of Cell.
NEW YORK - Newly published results from a randomized, Phase III trial show that the drug sunitinib malate (Sutent®) is more effective than the conventional treatment given as an initial therapy for patients with advanced kidney cancer.
